Pretreatment patient characteristics
| Characteristic (N = 62 unless stated) . | Number (%) with U-MRD* . | OR, P . |
|---|---|---|
| Age, median (range), y | ||
| <65 (n = 53) | 13 (24.5) | 0.4 (0.1-1.7), .23 |
| ≥65 (n = 9) | 4 (44.4) | |
| Rai stage | ||
| 0-II (n = 40) | 11 (29.7) | 2.2 (0.6-7.7), .23 |
| III-IV (n = 22) | 3 (15.0) | |
| B2M mg/L (n = 61) | ||
| <4.0 (n = 39) | 11 (28.2) | 1.1 (0.3-3.4), .94 |
| ≥4.0 (n = 22) | 6 (27.3) | |
| ZAP70 (n = 52) | ||
| Negative (n = 23) | 7 (30.4) | 1.4 (0.4-4.7), .61 |
| Positive (n = 29) | 7 (24.1) | |
| FISH (n = 61) | ||
| Del(13q) (n = 19) | 4 (21.1) | |
| No abnormalities (n = 21) | 5 (23.8) | |
| Trisomy 12 (n = 11) | 6 (54.5) | 4.8 (1.2-18.9), .02 |
| Del(11q) (n = 8) | 0 | |
| Del(17p) (n = 2) | 1 (50.0) | |
| IGHV mutation status | ||
| Mutated (n = 32) | 13 (41) | 4.4 (1.3-15.8), .02 |
| Unmutated (n = 30) | 4 (13) |
| Characteristic (N = 62 unless stated) . | Number (%) with U-MRD* . | OR, P . |
|---|---|---|
| Age, median (range), y | ||
| <65 (n = 53) | 13 (24.5) | 0.4 (0.1-1.7), .23 |
| ≥65 (n = 9) | 4 (44.4) | |
| Rai stage | ||
| 0-II (n = 40) | 11 (29.7) | 2.2 (0.6-7.7), .23 |
| III-IV (n = 22) | 3 (15.0) | |
| B2M mg/L (n = 61) | ||
| <4.0 (n = 39) | 11 (28.2) | 1.1 (0.3-3.4), .94 |
| ≥4.0 (n = 22) | 6 (27.3) | |
| ZAP70 (n = 52) | ||
| Negative (n = 23) | 7 (30.4) | 1.4 (0.4-4.7), .61 |
| Positive (n = 29) | 7 (24.1) | |
| FISH (n = 61) | ||
| Del(13q) (n = 19) | 4 (21.1) | |
| No abnormalities (n = 21) | 5 (23.8) | |
| Trisomy 12 (n = 11) | 6 (54.5) | 4.8 (1.2-18.9), .02 |
| Del(11q) (n = 8) | 0 | |
| Del(17p) (n = 2) | 1 (50.0) | |
| IGHV mutation status | ||
| Mutated (n = 32) | 13 (41) | 4.4 (1.3-15.8), .02 |
| Unmutated (n = 30) | 4 (13) |
B2M, β-2 microglobulin; FISH, fluorescence in situ hybridization; ZAP70, ζ-associated protein 70, by immunohistochemistry in BM.
MRD result from in BM (n = 57) where available or PBMC (n = 5). U-MRD defined for this analysis as undetectable MRD, regardless of assay sensitivity.